Hims & Hers gains as FDA panel endorses peptide BPC-157
Seeking Alpha ·
Shares of Hims & Hers Health ( HIMS ) rose more than 10% on Thursday after an FDA advisory panel voted to include a popular peptide known as BPC-157 in a list of molecules that compounding pharmacies use to make customized treatments.
AI 시장 분석
Shares of Hims & Hers Health surged over 10% on Thursday, driven by the FDA advisory committee's recommendation to approve the peptide BPC-157. This move establishes a legal foundation for the company to utilize popular ingredients in compounding treatments. Investors expect future regulatory easing to act as a positive momentum for earnings growth.
상승 영향
- Biotechnology — The FDA advisory committee's recommendation to approve the peptide BPC-157 is expected to accelerate the expansion of the customized treatment portfolio.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 39% · Bearish (Short) 61%
398 participants
Related News
- Live Oak targets at least $750M in annual Live Oak Express production while aiming for a minimum 10% DDA deposit mix
- AirIQ GAAP EPS of C$0.00, revenue of C$6.49M
- Getlink reports 1H results
- Eco (Atlantic) Oil & Gas Ltd. GAAP EPS of -$0.02
- Supermicro Introduces New Server Portfolio with 6th Gen AMD EPYC™ 9006 Series CPUs, Delivering 1.7x Generational Performance Improvements
- Chevron only Outperform-rated name among global oil majors initiated at Piper Sandler
